Krsnaa Diagnostics Limited — Investor Meet, 19-08-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Krsnaa Diagnostics (KRSNAA) reported Q1 FY26 revenue of ₹193.0 Cr (+13% YoY), EBITDA of ₹52.4 Cr (+19% YoY) with 27% margin, and PAT of ₹20.5 Cr (+15% YoY). The company secured the Rajasthan pathology PPP contract, a pure pathology project involving ₹200-250 Cr CAPEX for 42 mother labs & 135 satellite labs, targeting ₹300-350 Cr annual revenue from FY27. Retail momentum is strong, contributing 6% of revenue with touchpoints up 7x YoY, aiming for break-even by FY26 end. Management is confident about market share gains, leveraging cost leadership and PPP infrastructure.